ADORA3; ADORA2A; ADORA1; GPBAR1; DRD4; | |
TSHR; NPSR1; CXCR1; | |
RECQL; TDP1; PLA2G1B; CDA; PKM; ADK; PIK3R1; TK1; GLO1; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; HSD11B1; ALOX12; AKR1B10; NOX4; USP2; TNKS; PARP1; TNKS2; PYGL; PNP; POLB; CD38; | |
PTPN1; PTPRF; PTPN2; ACP1; | |
ACHE; | |
CFTR; | |
NEK6; PKN1; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; SYK; AXL; NEK2; FLT3; SRC; IGF1R; PTK2; AURKB; GSK3B; KDR; CDK1; PIM1; NUAK1; ALK; CDK6; | |
CA14; CA5B; CA3; CA7; CA5A; CA12; CA9; CA4; CA6; CA2; CA1; | |
AR; | |
RORC; | |
ESR1; ESR2; | |
NR1H4; | |
KDM4E; | |
MAOA; ALOX5; PTGS2; XDH; | |
MMP13; MMP12; MMP3; MMP2; MMP9; | |
BACE1; | |
STAT6; HIF1A; NFKB1; TP53; | |
SLC28A2; SLC28A1; SLC28A3; | |
ABCC1; ABCG2; | |
ITGAL; LMNA; MAPT; THPO; NPC1; APP; TTR; | |
L3MBTL1; SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Chloride channel | CFTR | Cystic fibrosis transmembrane conductance regulator | P13569 | CHEMBL4051 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | HSD11B1 | 11-beta-hydroxysteroid dehydrogenase 1 | P28845 | CHEMBL4235 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | PARP1 | Poly [ADP-ribose] polymerase-1 | P09874 | CHEMBL3105 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | PNP | Purine nucleoside phosphorylase | P00491 | CHEMBL4338 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | CD38 | Lymphocyte differentiation antigen CD38 | P28907 | CHEMBL4660 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group F | RORC | Nuclear receptor ROR-gamma | P51449 | CHEMBL1741186 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | SYK | Tyrosine-protein kinase SYK | P43405 | CHEMBL2599 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
Protein Phosphatase | PTPRF | Receptor-type tyrosine-protein phosphatase F (LAR) | P10586 | CHEMBL3521 |
Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
Protein Phosphatase | ACP1 | Low molecular weight phosphotyrosine protein phosphatase | P24666 | CHEMBL4903 |
SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | ITGAL | Leukocyte adhesion glycoprotein LFA-1 alpha | P20701 | CHEMBL1803 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | APP | Beta amyloid A4 protein | P05067 | CHEMBL2487 |
Unclassified | TTR | Transthyretin | P02766 | CHEMBL3194 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 6.461E-13 | 3.432E-10 | ADORA1, ADORA2A, AURKB, CA2, CA7, CD38, CDK6, CFTR, HIF1A, KDR, NEK2, NPC1, NPSR1, NR1H4, PARP1, PLA2G1B, PTGS2, SRC, SYK, TNKS, TNKS2 |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 5.638E-12 | 2.117E-09 | ADORA2A, AURKB, CA2, CA7, CFTR, HIF1A, NEK2, NPC1, NPSR1, NR1H4, PLA2G1B, PTGS2, SYK, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 4.398E-11 | 1.312E-08 | ABCG2, ACHE, ADORA2A, AKT1, ALK, APP, CAMK2B, CD38, CDA, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, FLT3, IGF1R, KDR, L3MBTL1, MAPT, MET, MMP9, NFKB1, PARP1, PKM, PTGS2, PYGL, SMN1, SMN2, STAT6, TK1, TP53, TTR, USP2, XDH |
MF | GO:0005488; binding | GO:0005524; ATP binding | 3.502E-10 | 8.707E-08 | ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, CAMK2B, CDK1, CDK6, CFTR, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MET, NEK2, NEK6, NUAK1, PIM1, PKM, PKN1, PTK2, PYGL, RECQL, SRC, SYK, TK1, TP53 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.629E-09 | 7.118E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
MF | GO:0005488; binding | GO:0020037; heme binding | 4.739E-09 | 8.744E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, MPO, NOX4, PTGS2, SRC |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 8.299E-09 | 1.401E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.053E-08 | 5.516E-06 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4, XDH |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.450E-08 | 5.981E-06 | AR, CYP3A4, ESR1, ESR2, HSD17B1, NPC1, NR1H4, RORC |
BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 5.427E-08 | 7.034E-06 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, NEK6, PKN1, SRC, SYK, TNKS |
MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 7.963E-08 | 9.797E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, DAPK1, GSK3B, NEK2, NEK6, NUAK1, PIM1, PKN1, SYK |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 2.435E-07 | 2.600E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 4.111E-07 | 4.163E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, PKN1, TNKS |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 8.188E-07 | 7.523E-05 | CYP1A2, CYP2C8, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 2.038E-06 | 1.681E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 2.053E-06 | 1.687E-04 | ALOX12, ALOX15, ALOX5, PTGS2 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 2.673E-06 | 2.116E-04 | AURKB, NEK2, TNKS, TNKS2 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 3.307E-06 | 2.580E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 4.058E-06 | 3.112E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 4.297E-06 | 3.283E-04 | ADORA1, ADORA2A, CA2, CA7, KDR, NPSR1, PARP1, PLA2G1B, SRC |
MF | Unclassified; | GO:0032403; protein complex binding | 4.677E-06 | 3.536E-04 | ACHE, ADORA1, FLT3, IGF1R, ITGAL, KDR, MMP12, MMP13, MMP9, PIK3R1, PKM, PTPN1, PTPN2, PTPRF, SRC, SYK, TSHR |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 4.804E-06 | 3.601E-04 | MMP12, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 6.598E-06 | 4.871E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C8 |
CC | GO:0044464; cell part | GO:0005829; cytosol | 6.729E-06 | 4.950E-04 | ACP1, ADK, AKR1B1, AKR1B10, AKT1, ALOX12, ALOX15, ALOX5, APP, AR, AURKB, CA1, CA2, CA3, CA7, CAMK2B, CDA, CDK1, CDK6, CFTR, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HSD17B1, LMNA, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKM, PKN1, PLA2G1B, PNP, PTK2, PTPN1, PTPN2, PYGL, SMN1, SMN2, SRC, STAT6, SYK, TK1, TNKS, TNKS2, TP53, XDH |
MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 7.071E-06 | 5.085E-04 | ADORA1, ADORA2A, ADORA3 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 7.723E-06 | 5.514E-04 | AR, CDK1, CFTR, ESR1, HIF1A, POLB, TNKS, TNKS2, TP53, USP2 |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 8.120E-06 | 5.722E-04 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, PARP1, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 8.611E-06 | 5.990E-04 | IGF1R, KDR, PTK2, SRC, SYK |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.003E-05 | 6.742E-04 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, PTGS2, TP53 |
BP | GO:0050896; response to stimulus | GO:0046626; regulation of insulin receptor signaling pathway | 1.060E-05 | 6.997E-04 | NR1H4, PIK3R1, PTPN1, PTPN2, SRC |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.246E-05 | 7.911E-04 | HIF1A, MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 1.619E-05 | 9.914E-04 | AKT1, MAPT, NOX4, PTGS2, TP53, XDH |
BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.682E-05 | 1.018E-03 | ADORA2A, APP, MAPT |
BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.682E-05 | 1.018E-03 | ADORA1, ADORA2A, ADORA3 |
MF | GO:0005488; binding | GO:0032052; bile acid binding | 1.682E-05 | 1.018E-03 | NR1H4, PLA2G1B, PYGL |
BP | GO:0009987; cellular process | GO:0010638; positive regulation of organelle organization | 1.783E-05 | 1.072E-03 | ALOX15, AURKB, GSK3B, HIF1A, KDR, MAPT, MET, MMP9, NEK2, NOX4, SRC, TNKS, TNKS2, TP53 |
BP | GO:0065007; biological regulation | GO:1904357; negative regulation of telomere maintenance via telomere lengthening | 1.882E-05 | 1.108E-03 | PARP1, SRC, TNKS, TNKS2 |
BP | GO:0050896; response to stimulus | GO:1904646; cellular response to amyloid-beta | 1.882E-05 | 1.108E-03 | APP, GSK3B, IGF1R, PARP1 |
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 2.186E-05 | 1.263E-03 | AKT1, MAPT, PTPN1, TP53 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.206E-05 | 1.267E-03 | AKT1, HIF1A, MMP9, PTGS2, PTPN1, SRC |
BP | GO:0051179; localization | GO:2001225; regulation of chloride transport | 2.393E-05 | 1.357E-03 | CA2, CA7, CFTR |
BP | GO:0048511; rhythmic process | GO:0042752; regulation of circadian rhythm | 2.633E-05 | 1.482E-03 | ADORA1, ADORA2A, DRD4, RORC, TP53, USP2 |
BP | GO:0051179; localization | GO:0034502; protein localization to chromosome | 2.655E-05 | 1.482E-03 | AURKB, CDK1, ESR1, TNKS, TNKS2 |
BP | GO:0051179; localization | GO:0006909; phagocytosis | 2.883E-05 | 1.589E-03 | ADORA1, ADORA2A, ALOX15, AXL, ITGAL |
BP | GO:0002376; immune system process | GO:0002683; negative regulation of immune system process | 3.105E-05 | 1.682E-03 | ADORA1, ADORA2A, ALOX15, AXL, CDK6, CYP19A1, MMP12, PIK3R1, PKN1, PTPN2, STAT6 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.125E-05 | 1.689E-03 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0032501; multicellular organismal process | GO:0060736; prostate gland growth | 3.276E-05 | 1.753E-03 | AR, CYP19A1, ESR1 |
BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 3.491E-05 | 1.822E-03 | CDK6, GSK3B, KDR, PIK3R1, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 3.504E-05 | 1.822E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC, THPO |
BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 3.514E-05 | 1.822E-03 | SLC28A2, SLC28A3 |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.514E-05 | 1.822E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.514E-05 | 1.822E-03 | ESR1, ESR2 |
MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 3.514E-05 | 1.822E-03 | SLC28A1, SLC28A3 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.514E-05 | 1.822E-03 | ALOX12, ALOX15 |
MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 3.514E-05 | 1.822E-03 | SLC28A2, SLC28A3 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.687E-05 | 1.894E-03 | AKT1, HIF1A, LMNA, PTGS2, SRC, TP53 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 3.769E-05 | 1.922E-03 | CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0008152; metabolic process | GO:0030574; collagen catabolic process | 4.258E-05 | 2.122E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.349E-05 | 2.147E-03 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 4.349E-05 | 2.147E-03 | CYP1A2, CYP2C8, CYP3A4 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 4.670E-05 | 2.265E-03 | AKT1, HIF1A, NOX4, NR1H4, PIK3R1, PTPN2, PYGL |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 4.817E-05 | 2.326E-03 | AURKB, NEK2, TNKS, TNKS2 |
MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 5.061E-05 | 2.417E-03 | ABCG2, ACHE, ADORA1, ADORA2A, AKT1, AR, AXL, CAMK2B, CDA, FLT3, HIF1A, ITGAL, MAPT, NFKB1, PIK3R1, PTGS2, PYGL, TP53, TTR, XDH |
BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 5.104E-05 | 2.432E-03 | AXL, CSNK2A1, DRD4, ESR1, GSK3B, RORC, SRC, TP53, USP2 |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 5.298E-05 | 2.513E-03 | AKT1, HIF1A, NFKB1, PTPN2, SRC |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 5.629E-05 | 2.636E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 5.629E-05 | 2.636E-03 | ADORA2A, CA2, CA7 |
BP | GO:0009987; cellular process | GO:1900103; positive regulation of endoplasmic reticulum unfolded protein response | 5.629E-05 | 2.636E-03 | PIK3R1, PTPN1, PTPN2 |
BP | GO:0065007; biological regulation | GO:0045124; regulation of bone resorption | 6.062E-05 | 2.809E-03 | CA2, CD38, SRC, SYK |
BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.485E-05 | 2.954E-03 | ADORA1, ADORA2A, CYP19A1, NFKB1, NR1H4, PTPN2 |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 6.763E-05 | 3.069E-03 | ADORA2A, AKT1, CYP1B1, DAPK1, GSK3B, MAPT, MMP9, NOX4, PTGS2, PTPN2, SRC, TP53, XDH |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 6.978E-05 | 3.146E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
BP | GO:0032502; developmental process | GO:0060065; uterus development | 7.133E-05 | 3.190E-03 | CYP19A1, ESR1, SRC |
BP | GO:0008283; cell proliferation | GO:0008285; negative regulation of cell proliferation | 7.611E-05 | 3.361E-03 | ADORA1, ADORA2A, ADORA3, APP, AR, CDK6, CYP1B1, LMNA, NOX4, PKN1, PTGS2, PTPN2, TP53, XDH |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 7.889E-05 | 3.456E-03 | ADK, AKR1B1, AKT1, ALOX5, AR, AURKB, CAMK2B, CDK1, CDK6, CSNK2A1, ESR1, ESR2, GSK3B, HIF1A, L3MBTL1, LMNA, NEK2, NEK6, NFKB1, NR1H4, NUAK1, PARP1, PIM1, PKN1, POLB, PTPN2, RECQL, RORC, SMN1, SMN2, SRC, STAT6, TNKS, TP53, USP2 |
CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 7.929E-05 | 3.467E-03 | ABCC1, ADORA1, ADORA2A, ADORA3, ALK, APP, AXL, BACE1, CFTR, DRD4, FLT3, IGF1R, KDR, MET, NPC1, NPSR1, PTPRF, SLC28A1, SLC28A2, SLC28A3, TSHR |
BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 7.958E-05 | 3.473E-03 | CDA, HSD17B10, PKM, TK1, TP53 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 9.041E-05 | 3.883E-03 | AXL, CDK1, CSNK2A1, FLT3, PKM |
BP | GO:0008283; cell proliferation | GO:0048661; positive regulation of smooth muscle cell proliferation | 9.041E-05 | 3.883E-03 | AKR1B1, AKT1, MMP2, MMP9, PTGS2 |
BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 1.050E-04 | 4.322E-03 | SLC28A1, SLC28A3 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.050E-04 | 4.322E-03 | CA2, CA7 |
BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 1.050E-04 | 4.322E-03 | SLC28A1, SLC28A3 |
BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.050E-04 | 4.322E-03 | GPBAR1, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0050473; arachidonate 15-lipoxygenase activity | 1.050E-04 | 4.322E-03 | ALOX15, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.050E-04 | 4.322E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.050E-04 | 4.322E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.050E-04 | 4.322E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.050E-04 | 4.322E-03 | GPBAR1, NR1H4 |
CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.050E-04 | 4.322E-03 | ADORA1, ADORA2A |
BP | GO:0022610; biological adhesion | GO:0045785; positive regulation of cell adhesion | 1.068E-04 | 4.389E-03 | AKT1, ALOX12, ALOX15, CDK6, GSK3B, KDR, PIK3R1, PNP, SRC, SYK |
BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 1.087E-04 | 4.438E-03 | MMP12, MMP13, MMP2, MMP3, MMP9 |
CC | GO:0044464; cell part | GO:0030673; axolemma | 1.088E-04 | 4.438E-03 | ADORA1, ADORA2A, MAPT |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 1.185E-04 | 4.787E-03 | ABCG2, APP, CA12, CA2, CA7, CD38, CFTR, DRD4, ESR1, HIF1A, NPSR1, PLA2G1B, TP53 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.225E-04 | 4.911E-03 | AKR1B1, AKT1, AR, CFTR, SRC |
CC | GO:0044464; cell part | GO:0034774; secretory granule lumen | 1.299E-04 | 5.144E-03 | ALOX5, APP, CDA, MPO, NFKB1, PKM, PNP, PYGL, TTR |
BP | GO:0008152; metabolic process | GO:0043174; nucleoside salvage | 1.315E-04 | 5.189E-03 | ADK, CDA, TK1 |
MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 1.315E-04 | 5.189E-03 | AURKB, CDK1, PKN1 |
BP | GO:0032501; multicellular organismal process | GO:0043536; positive regulation of blood vessel endothelial cell migration | 1.347E-04 | 5.284E-03 | AKT1, HIF1A, KDR, PTGS2 |
BP | GO:0009987; cellular process | GO:0010639; negative regulation of organelle organization | 1.393E-04 | 5.448E-03 | AKT1, LMNA, MAPT, MET, NEK2, PARP1, SRC, TNKS, TNKS2 |
BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 1.437E-04 | 5.583E-03 | ALOX5, CDA, CXCR1, ITGAL, MMP9, MPO, NFKB1, PKM, PNP, PYGL, TTR |
BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 1.438E-04 | 5.583E-03 | ABCG2, APP, CA2, CA7, CD38, CFTR, DRD4, ESR1, HIF1A, NPSR1, PLA2G1B, TP53 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.471E-04 | 5.701E-03 | AKT1, LMNA, MMP9, TP53 |
MF | Unclassified; | GO:0004872; receptor activity | 1.746E-04 | 6.635E-03 | ADORA1, ADORA2A, ADORA3, ALK, AR, AXL, CXCR1, DRD4, ESR1, ESR2, FLT3, GPBAR1, IGF1R, ITGAL, KDR, MET, NPC1, NPSR1, NR1H4, PTPRF, RORC, TSHR |
BP | GO:0008152; metabolic process | GO:0006091; generation of precursor metabolites and energy | 1.829E-04 | 6.915E-03 | AKR1B1, AKT1, CYP19A1, CYP1A2, GSK3B, NOX4, PKM, PYGL, XDH |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 2.092E-04 | 7.721E-03 | TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.092E-04 | 7.721E-03 | PTPN1, PTPN2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.092E-04 | 7.721E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 2.092E-04 | 7.721E-03 | ESR1, ESR2 |
BP | GO:0022610; biological adhesion | GO:0022407; regulation of cell-cell adhesion | 2.116E-04 | 7.795E-03 | ADORA2A, AKT1, ALOX12, ALOX15, PIK3R1, PNP, PTK2, PTPN2, SRC, SYK |
BP | GO:0051179; localization | GO:0032890; regulation of organic acid transport | 2.223E-04 | 8.092E-03 | ADORA1, ADORA2A, AKT1, SYK |
BP | Unclassified; | GO:0032845; negative regulation of homeostatic process | 2.234E-04 | 8.106E-03 | ADORA1, CD38, PARP1, SRC, TNKS, TNKS2 |
BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 2.279E-04 | 8.228E-03 | APP, AURKB, GSK3B, MET, MMP9, PTPRF, SRC |
BP | GO:0050896; response to stimulus | GO:0014074; response to purine-containing compound | 2.407E-04 | 8.633E-03 | ADORA2A, APP, CFTR, NOX4, PTGS2, TP53 |
BP | GO:0008152; metabolic process | GO:0006066; alcohol metabolic process | 2.483E-04 | 8.862E-03 | AKR1B1, AKR1B10, APP, CFTR, CYP1B1, CYP3A4, NPC1, TTR |
BP | GO:0050896; response to stimulus | GO:0071498; cellular response to fluid shear stress | 2.528E-04 | 8.967E-03 | CA2, PTGS2, SRC |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.528E-04 | 8.967E-03 | CYP1A1, POLB, TP53 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 2.544E-04 | 9.007E-03 | AXL, CYP1A1, CYP1A2, MPO, NFKB1, NR1H4, PTGS2, SRC |
BP | GO:0008152; metabolic process | GO:1901657; glycosyl compound metabolic process | 2.590E-04 | 9.119E-03 | ADK, AKR1B1, AKR1B10, CDA, PNP, TK1 |
BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 2.592E-04 | 9.119E-03 | AURKB, CSNK2A1, NEK2, NEK6, TNKS |
BP | GO:0032502; developmental process | GO:0045597; positive regulation of cell differentiation | 2.838E-04 | 9.870E-03 | AKT1, APP, AR, AXL, CA2, CAMK2B, HIF1A, KDR, MAPT, NFKB1, PARP1, PNP, PTGS2, SYK, THPO |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 2.729E-22 | 2.971E-18 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.978E-17 | 4.308E-14 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CFTR |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.379E-15 | 6.291E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.659E-14 | 1.655E-11 | AR, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, CDA, ESR1, ESR2, GLO1, L3MBTL1, MMP12, MMP13, MMP2, MMP3, MMP9, NR1H4, PARP1, PTPN1, RORC, TK1, TNKS, TP53 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 1.672E-21 | 3.261E-19 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 1.628E-10 | 1.587E-08 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; TP53; MET |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 4.100E-10 | 2.665E-08 | HSD17B1; ALOX5; HSD17B2; CYP1A1; CYP1B1; PTGS2; CYP19A1; IGF1R |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.075E-09 | 5.243E-08 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; PTGS2; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AR; CDK6; AKT1; MET; TP53 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 1.409E-09 | 5.495E-08 | HSD11B1; HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.870E-08 | 9.327E-07 | CDA; PLA2G1B; MAOA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; PTGS2; CYP3A4; CYP19A1; HSD17B10; HSD11B1; PNP; HSD17B1; ALOX5; HSD17B2; CD38; TK1; XDH; CYP2C8; PKM; AKR1B10; CYP1A2; CYP1A1 |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.870E-07 | 4.559E-06 | GSK3B; SRC; AKT1; PIK3R1; ESR1; NFKB1; ESR2 |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.131E-07 | 3.149E-06 | PKM; FLT3; AKT1; PIK3R1; TP53; MET; HIF1A |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.624E-07 | 5.117E-06 | GSK3B; SYK; CSNK2A1; CDK1; AKT1; CD38; PIK3R1; ITGAL; TP53; NFKB1 |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 6.370E-07 | 8.894E-06 | GSK3B; CDK6; SYK; KDR; AKT1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 2.263E-07 | 4.904E-06 | PTPN1; CSNK2A1; SRC; ACP1; MET; PTPRF; IGF1R |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 8.073E-07 | 1.049E-05 | GSK3B; AR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 6.385E-07 | 8.894E-06 | CDK6; AKT1; PIK3R1; PTGS2; TP53; NFKB1; PTK2 |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.604E-07 | 8.162E-06 | HSD11B1; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; PTGS2 |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 9.834E-07 | 1.198E-05 | FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.360E-06 | 1.560E-05 | SRC; KDR; AKT1; PIK3R1; PTGS2; PTK2 |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 1.664E-06 | 1.708E-05 | SRC; MMP2; AKT1; PIK3R1; ESR1; MMP9; ESR2 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 2.037E-06 | 1.891E-05 | CDK6; SRC; AKT1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 2.885E-06 | 2.557E-05 | POLB; CDK6; PKM; SYK; SRC; CDK1; PIK3R1; TP53; NFKB1 |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.986E-06 | 1.891E-05 | CAMK2B; CDK6; AKT1; PIK3R1; TP53; IGF1R |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 1.499E-06 | 1.624E-05 | CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; PTGS2 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.176E-06 | 2.693E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; NFKB1; PTPRF |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.808E-06 | 2.856E-05 | APP; CYP2C8; MAOA; ALOX5; ALOX15; ALOX12; PTGS2 |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 3.348E-06 | 2.720E-05 | CDK6; AKT1; PIK3R1; TP53; MET; IGF1R |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.125E-07 | 8.894E-06 | CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.387E-06 | 3.890E-05 | GSK3B; SRC; AKT1; PIK3R1; TP53; ESR1; HIF1A |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.021E-06 | 4.193E-05 | ABCC1; ADORA3; ADORA1; AKT1; PIK3R1; TP53; NFKB1 |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.370E-05 | 8.903E-05 | GSK3B; CDK6; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 1.096E-05 | 7.367E-05 | CAMK2B; GSK3B; SRC; AKT1; PIK3R1; PTK2 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 1.988E-05 | 1.140E-04 | CAMK2B; ADORA2A; ADORA1; AKT1; PIK3R1; CFTR; NFKB1; TSHR |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 2.214E-05 | 1.233E-04 | GSK3B; SRC; KDR; AKT1; PIK3R1; MET; PTK2; IGF1R |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 3.024E-05 | 1.594E-04 | ADORA2A; SRC; KDR; AKT1; PIK3R1; ITGAL; MET; IGF1R |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 5.528E-05 | 2.635E-04 | ABCC1; CDK6; PIM1; CYP1B1; PTGS2; TP53; MMP9; MET; NFKB1 |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 2.879E-05 | 1.560E-04 | CAMK2B; AKT1; PIK3R1; HIF1A; NFKB1; IGF1R |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 1.741E-05 | 1.061E-04 | ALK; CDK6; AKT1; PIK3R1; TP53 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 4.175E-05 | 2.087E-04 | MMP3; AKT1; PIK3R1; PTGS2; MMP9; NFKB1 |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 3.658E-06 | 2.853E-05 | DAPK1; SRC; MMP2; MMP9; TP53 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.741E-05 | 1.061E-04 | ADORA1; AKT1; PIK3R1; PTGS2; TSHR |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 1.900E-05 | 1.123E-04 | FLT3; PIM1; AKT1; PIK3R1; NFKB1 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 6.796E-05 | 2.945E-04 | CAMK2B; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.045E-04 | 4.337E-04 | GSK3B; CXCR1; SRC; AKT1; PIK3R1; NFKB1; PTK2 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.891E-05 | 1.997E-04 | CDK6; AKT1; PIK3R1; TP53; NFKB1 |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.591E-04 | 6.203E-04 | PARP1; LMNA; AKT1; PIK3R1; TP53; NFKB1 |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.334E-05 | 2.807E-04 | GSK3B; SYK; AKT1; PIK3R1; NFKB1 |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.529E-04 | 6.087E-04 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; PTPRF |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 6.334E-05 | 2.807E-04 | CDK6; AKT1; PIK3R1; TP53; NFKB1 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 3.061E-04 | 1.085E-03 | THPO; PIM1; AKT1; STAT6; PIK3R1; PTPN2 |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 3.433E-04 | 1.174E-03 | PLA2G1B; KDR; AKT1; PIK3R1; MET; NFKB1; IGF1R |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 2.940E-04 | 1.062E-03 | MMP2; PIM1; AKT1; PIK3R1; NFKB1 |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.334E-05 | 2.807E-04 | HSD11B1; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 5.541E-05 | 2.635E-04 | CA2; NR1H4; CYP3A4; CFTR; ABCG2 |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.103E-04 | 7.888E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa04064 | NF-kappa B signaling pathway_Homo sapiens_hsa04064 | 2.001E-04 | 7.649E-04 | SYK; CSNK2A1; PARP1; PTGS2; NFKB1 |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 7.354E-04 | 2.241E-03 | POLB; GSK3B; AKT1; PIK3R1; ITGAL; TP53; NFKB1 |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 6.011E-04 | 1.921E-03 | MMP2; PIK3R1; ITGAL; MMP9; PTK2 |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 8.995E-04 | 2.698E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.206E-03 | 6.234E-03 | CAMK2B; SRC; CD38; PIK3R1; PTGS2 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.031E-03 | 3.047E-03 | GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.876E-03 | 7.580E-03 | BACE1; APP; GSK3B; MAPT; HSD17B10 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.684E-03 | 9.451E-03 | CAMK2B; SYK; SRC; AKT1; NFKB1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 2.473E-03 | 6.698E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 2.473E-03 | 6.698E-03 | CDK1; AKT1; PIK3R1; IGF1R |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.759E-03 | 7.370E-03 | CAMK2B; PKM; AKT1; PYGL |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 3.874E-03 | 9.810E-03 | CAMK2B; ACHE; AKT1; PIK3R1 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.414E-03 | 1.320E-02 | SYK; SRC; AKT1; PIK3R1 |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 3.067E-03 | 7.973E-03 | GSK3B; AKT1; PIK3R1; NFKB1 |
hsa04972 | Pancreatic secretion_Homo sapiens_hsa04972 | 2.295E-03 | 6.392E-03 | CA2; PLA2G1B; CD38; CFTR |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 4.814E-03 | 1.203E-02 | ALOX5; AKT1; PIK3R1; NFKB1 |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 5.572E-03 | 1.341E-02 | CAMK2B; AR; CDK1; IGF1R |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 5.680E-04 | 1.846E-03 | AKT1; PIK3R1; MET; HIF1A |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 5.732E-03 | 1.347E-02 | AKT1; PIK3R1; CFTR; IGF1R |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 5.732E-03 | 1.347E-02 | GSK3B; CDK6; CDK1; TP53 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 7.130E-03 | 1.598E-02 | SYK; AKT1; PIK3R1; NFKB1 |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 4.475E-04 | 1.505E-03 | GSK3B; AKT1; PIK3R1; TP53 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.066E-03 | 3.104E-03 | SRC; PIK3R1; MET; PTK2 |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 2.270E-04 | 8.351E-04 | GSK3B; AKT1; PIK3R1; TP53 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 9.171E-03 | 1.944E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.131E-02 | 2.345E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 9.171E-03 | 1.944E-02 | GSK3B; AKT1; PIK3R1; IGF1R |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 9.621E-03 | 2.017E-02 | SYK; CXCR1; AKT1; PIK3R1 |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 5.360E-04 | 1.771E-03 | CYP2C8; CYP1A2; CYP1A1; CYP3A4 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.700E-02 | 3.218E-02 | CXCR1; SRC; KDR; MET; IGF1R |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 6.362E-04 | 2.001E-03 | CXCR1; SRC; MET; NFKB1 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 6.724E-04 | 2.081E-03 | CYP2C8; MAOA; CYP1A2; CYP3A4 |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 1.857E-02 | 3.417E-02 | CXCR1; THPO; FLT3; KDR; MET |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.584E-02 | 3.058E-02 | ADORA3; ADORA1; AKT1; PIK3R1 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.201E-02 | 3.827E-02 | ADORA2A; ADORA3; ADORA1; DRD4; TSHR |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.848E-02 | 3.417E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
hsa00230 | Purine metabolism_Homo sapiens_hsa00230 | 1.883E-02 | 3.432E-02 | PNP; PKM; ADK; XDH |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.215E-02 | 3.827E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.560E-02 | 3.042E-02 | CAMK2B; SRC; MMP2 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.652E-02 | 3.159E-02 | SYK; AKT1; PIK3R1 |
hsa04640 | Hematopoietic cell lineage_Homo sapiens_hsa04640 | 1.426E-02 | 2.868E-02 | THPO; FLT3; CD38 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.053E-02 | 3.674E-02 | AKT1; PIK3R1; HIF1A |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 2.001E-02 | 3.612E-02 | PIK3R1; NFKB1; PTK2 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 2.329E-02 | 3.949E-02 | AKT1; PIK3R1; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 2.216E-02 | 3.827E-02 | AKT1; PIK3R1; NFKB1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 1.405E-04 | 5.707E-04 | CDA; TK1; CYP3A4; XDH |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 7.075E-03 | 1.598E-02 | SYK; AKT1; PIK3R1 |
hsa00240 | Pyrimidine metabolism_Homo sapiens_hsa00240 | 2.272E-02 | 3.887E-02 | CDA; PNP; TK1 |
hsa04971 | Gastric acid secretion_Homo sapiens_hsa04971 | 8.927E-03 | 1.934E-02 | CAMK2B; CA2; CFTR |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 4.994E-03 | 1.233E-02 | AKT1; PIK3R1; HIF1A |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 8.080E-05 | 3.425E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 5.980E-03 | 1.388E-02 | AKT1; PIK3R1; IGF1R |
hsa04115 | p53 signaling pathway_Homo sapiens_hsa04115 | 7.366E-03 | 1.632E-02 | CDK6; CDK1; TP53 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 6.244E-03 | 1.432E-02 | RORC; STAT6; NFKB1 |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.066E-03 | 5.924E-03 | ABCC1; CFTR; ABCG2 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.763E-02 | 4.645E-02 | AKT1; PIK3R1 |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.284E-02 | 2.607E-02 | AKR1B10; AKR1B1 |
hsa00620 | Pyruvate metabolism_Homo sapiens_hsa00620 | 2.218E-02 | 3.827E-02 | PKM; GLO1 |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.541E-02 | 3.035E-02 | POLB; PARP1 |
hsa00051 | Fructose and mannose metabolism_Homo sapiens_hsa00051 | 1.453E-02 | 2.891E-02 | AKR1B10; AKR1B1 |
hsa00040 | Pentose and glucuronate interconversions_Homo sapiens_hsa00040 | 1.818E-02 | 3.409E-02 | AKR1B10; AKR1B1 |
hsa00760 | Nicotinate and nicotinamide metabolism_Homo sapiens_hsa00760 | 1.203E-02 | 2.468E-02 | PNP; CD38 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.663E-03 | 1.679E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.241E-04 | 1.128E-03 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
NA: NA | Menopausal disorder | NA | ESR1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
J00-J99: Diseases of the respiratory system | Influenza virus | J11.1 | HSD11B1 |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; PTGS2; ADORA3 |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; SYK; MMP12; PTGS2 |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; PTGS2; PTGS2; ADORA2A; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
NA: NA | Geographic retinal atrophy | NA | APP |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
NA: NA | Rheumatold arthritis | NA | PTGS2; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; SYK; MMP3; PTGS2; PTGS2; PTGS2; PTGS2; PNP |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; PTGS2; PTGS2; PTGS2; ESR1 |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HSD11B1; GPBAR1 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; ADK |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; PKM; CDA; SYK; FLT3; CA9; MMP2; SRC; IGF1R; AURKB; HIF1A; MMP9; PTK2; TP53; KDR; KDR; KDR; TK1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD4 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Mild to moderate alzheimer disease | G30 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; APP |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
I00-I99: Diseases of the circulatory system | Cardiomyopathy | I42.0 | TTR |
I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
C00-D49: Neoplasms | Refractory cutaneous T-cell lymphoma | NA | PNP |
C00-D49: Neoplasms | Recurrent epithelial ovarian or primary peritoneal cancer | C78 | PARP1 |
C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; MMP2; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory skin condition | L00-L99 | PARP1 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; AKT1; MET; CSNK2A1; SYK; FLT3; FLT3; CA9; MMP2; ACHE; PTGS2; SRC; IGF1R; CD38; GSK3B; ADORA3; HIF1A; CDK1; MMP9; NFKB1; PIM1; PARP1; PTK2; TP53; ESR1; ESR1; CA1; KDR; TK1; APP |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Renal transplantation | D89.8 | ITGAL |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | HSD11B1; PTPN1; PTPN1; PTGS2; NFKB1; GPBAR1 |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
NA: NA | Joint and muscular pain | NA | PTGS2 |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ITGAL; ALOX5; FLT3 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; ESR1; APP |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2 |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Lipid metabolism disorder | E75-E78 | HSD11B1 |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ITGAL; SYK; ADORA1; PNP; ESR1 |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; MMP12; MMP12; ADORA2A |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | SYK |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | B-cell lymphoma | C85.1 | SYK |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
H00-H59: Diseases of the eye and adnexa | Macular degeneration | H35.3 | APP |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | HSD11B1; ALOX5; MMP12 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE; ADORA1 |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; ADORA1; XDH |
C00-D49: Neoplasms | Melanoma | C43 | PARP1; KDR; KDR |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
C00-D49: Neoplasms | Glioma | C71 | KDR; APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
C00-D49: Neoplasms | B-cell acute lymphoblastic leukemia | NA | PNP |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2 |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR; ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
H00-H59: Diseases of the eye and adnexa | Dry eye disease | H16.229 | ITGAL |
G00-G99: Diseases of the nervous system G00-G99 | Brain ischaemia | G45.9, I67.8 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; PARP1 |
I00-I99: Diseases of the circulatory system | Cerebrovascular disorders | I60-I69 | PARP1 |
I00-I99: Diseases of the circulatory system | Cerebral amyloid angiopathy | I68.0 | APP |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic syndrome x | E88.81 | HSD11B1 |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; ESR1; TK1 |
NA: NA | Male hypogonadism | NA | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3; PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | HSD11B1 |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | ITGAL; FLT3 |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1; TK1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; ESR1; ESR1; KDR; KDR; KDR |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1 |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADORA2A |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Amyloidosis | E85 | APP; TTR |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1 |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR; ESR1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R; ESR1; ESR1 |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR; ESR1 |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
NA: NA | Colour dead tissues | NA | PTPN1 |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SYK; SRC; CD38; AURKB; TP53 |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
NA: NA | Hepatitis C virus infection | NA | ADORA3 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5; SYK |
C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | TTR amyloidosis | E85 | TTR |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | HSD11B1; CA4; CA4 |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; PTGS2 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2 |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
NA: NA | Postmenopausal disorder | NA | ESR1 |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53; TK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Permanent and transient stroke | G45.9, I61-I63 | PARP1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; PTGS2; KDR; TK1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
G00-G99: Diseases of the nervous system G00-G99 | Diagnostic imaging | G30, I73.9 | APP |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; PTGS2; XDH; PNP |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADORA3; ADORA2A; ADORA1; CA1; CA1 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
NA: NA | Edema | NA | CA2 |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; ADORA2A; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; PKM; MMP13; ADK; ACHE; PTGS2; PTGS2; PTGS2; PTGS2; IGF1R; ADORA2A; CDK1; ESR1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Moderate-to-severe plaque psoriasis | L40 | PNP |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; ACHE; CYP3A4 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2 |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12 |
NA: NA | Gonorrheal vaginitis | NA | ESR1 |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
A00-B99: Certain infectious and parasitic diseases | Diarrhea | A09, K59.1 | CFTR |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
C00-D49: Neoplasms | Multiple myeloma | C90 | SRC; IGF1R; CD38 |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1; ESR1; ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC; ESR1 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; PARP1; KDR; KDR; KDR; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR; ESR1 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Age related macular degeneration | H35.3 | APP |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR; CFTR |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2; PTGS2 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5; PTGS2; PTGS2 |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; SYK; SYK; MMP12; PTGS2; ADORA2A; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Ataxia telangiectasia | G11.3 | PARP1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
C00-D49: Neoplasms | Allergic conjunctivitis | C91.0, H10, H10.45, T78.4 | ITGAL |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; SYK; ADORA1 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; ACHE; ACHE; ACHE; PTGS2; GSK3B; APP |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
A00-B99: Certain infectious and parasitic diseases | HIV-associated diarrhoea | A09 | CFTR |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; HSD11B1; HSD11B1; PTPN1; GSK3B; ADORA1 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1 |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; ACHE |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | HSD11B1; PTPN1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | HSD11B1 |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | SYK |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; PTGS2; IGF1R; IGF1R; KDR |